UMC has an award-winning research team, doing pioneering work in pharmacovigilance
Developing the science behind the practice of pharmacovigilance has been a key priority for UMC for nearly four decades.
A primary focus for us is to create and develop data-driven discovery in support of improved detection and exploration of signals. UMC was the first to develop and deploy computational pattern-discovery across an entire database of reports of suspected adverse effects. We pioneered methods to identify, analyse and explain possible adverse effects in longitudinal patient records. We have also been at the forefront of pharmacovigilance development in resource-limited settings, where a prominent part of healthcare delivery is through public health programmes.
beyond identifying first signals to seeking explanations why particular patients are harmed, including drug-drug interactions and other risk factors, such as age and sex. Our primary aim is to enable wise therapeutic decisions by health professionals and patients; methods for structured benefit-harm assessment are an important part of this.
the best possible tools for pharmacovigilance in general, and in support of all member countries in the WHO Programme for International Drug Monitoring. Since 2015 all UMC scientific papers have been published as open access – free, immediate and online. We are also engaged in technical exchanges with member countries, and with the international scientific community at meetings and conferences across the world.